Drug Trial Radar · NCT01556997
Perindopril Amlodipine for the Treatment of Hypertension
Last checked: Nov 20, 2026Latest source record: Sep 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
837
Actual
Start
Feb 2012
Primary completion
Feb 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- Symplmed Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.
Conditions
- Essential Hypertension
Interventions
XOMA 985Drug
PERa/AMLb capsule taken once daily by mouth for six weeks
Amlodipine BesylateDrug
AMLb capsule taken once daily by mouth for six weeks
Perindopril ErbumineDrug
PERe capsule taken once daily by mouth for six weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).Time frame: Day 0 to Day 42
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Muscle Shoals, Alabama
Site not named
Glendale, Arizona
Site not named
Greenbrae, California
Site not named
Los Angeles, California
Site not named
Santa Ana, California
Site not named
Denver, Colorado
Site not named
DeLand, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Miami, Florida
Site not named
Palm Harbor, Florida
Site not named
Port Orange, Florida
Site not named
Marietta, Georgia
Site not named
Gurnee, Illinois
Site not named
Indianapolis, Indiana
Site not named
Wichita, Kansas
Site not named
Louisville, Kentucky
Site not named
Metairie, Louisiana
Site not named
Auburn, Maine
Site not named
Baltimore, Maryland
Site not named
Olive Branch, Mississippi
Site not named
Butte, Montana
Site not named
Berlin, New Jersey
Site not named
Greensboro, North Carolina
Site not named
Hickory, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Kettering, Ohio
Site not named
Lyndhurst, Ohio
Site not named
Marion, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Tulsa, Oklahoma
Site not named
Eugene, Oregon
Site not named
Mt. Pleasant, South Carolina
Site not named
Simpsonville, South Carolina
Site not named
Bristol, Tennessee
Site not named
Austin, Texas
Site not named
Corpus Christi, Texas
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.